Related Experiment Video
Updated: Aug 11, 2026
Generation of an Orthotopic Xenograft of Pancreatic Cancer Cells by Ultrasound-Guided Injection
Published on: November 1, 2021
Transcriptional anti-angiogenesis therapy of human pancreatic cancer
Keping Xie1, Daoyan Wei, Suyun Huang
1Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. kepxie@mail.mdanderson.org
Abstract:
Pancreatic cancer angiogenesis has been attributed to genetic and epigenetic alterations (e.g., oncogene activation and suppressor inactivation) and a chaotic tumor microenvironment (e.g., hypoxia, acidosis, free radical stress and imbalanced growth factor production). Those diverse "upstream signal" factors appear to converge their signaling pathways on limited sets of nuclear transcription factors (e.g., Sp1, Stat3 and NF-kappaB). Aberrant activities of these factors confer a tremendous survival and growth advantage to existing and/or emerging malignant cells through alteration of the expression and functions of their diverse "downstream effector" factors (e.g., VEGF and IL-8). Therefore, targeting a single transcription factor can affect the malignant phenotype more profoundly than just targeting any single upstream signal and/or downstream effector factor.
Insights
Targeting key nuclear transcription factors, like Sp1, Stat3, and NF-kappaB, offers a potent strategy against pancreatic cancer. These factors control essential cancer cell survival and growth pathways, making them crucial therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Pancreatic cancer angiogenesis is driven by genetic/epigenetic changes and a complex tumor microenvironment.
- Factors like hypoxia, acidosis, and oxidative stress contribute to aberrant signaling.
- These signals converge on nuclear transcription factors, influencing tumor progression.
Purpose of the Study:
- To investigate the role of nuclear transcription factors in pancreatic cancer.
- To identify key signaling convergence points in pancreatic tumor development.
- To evaluate the therapeutic potential of targeting transcription factors.
Main Methods:
- Analysis of genetic and epigenetic alterations in pancreatic cancer.
- Assessment of tumor microenvironment factors.
- Identification and characterization of key nuclear transcription factors (e.g., Sp1, Stat3, NF-kappaB).
- Evaluation of downstream effector gene expression (e.g., VEGF, IL-8).
Main Results:
- Genetic and microenvironmental factors converge on specific transcription factors.
- Aberrant transcription factor activity promotes cancer cell survival and growth.
- Targeting transcription factors impacts multiple downstream effectors like VEGF and IL-8.
Conclusions:
- Nuclear transcription factors are central regulators of pancreatic cancer progression.
- Targeting transcription factors (Sp1, Stat3, NF-kappaB) is a promising therapeutic strategy.
- This approach offers a more profound impact on the malignant phenotype than targeting single upstream or downstream factors.
More Related Videos
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
